#None #TransCode #TTX-MC138 #Dr. Janicot

TransCode Therapeutics Strengthens Leadership Team with Dr. Michel Janicot's Appointment

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has made a significant move in enhancing its executive team by appointing Dr. Michel Janicot as the new Senior Development Officer. This strategic addition comes as part of the company’s ongoing commitment to innovating immuno-oncology and targeted cancer therapies, particularly for advanced malignancies. The announcement was made on November 17, 2025.

Dr. Janicot comes with an impressive background, boasting over 35 years of rich experience in the pharmaceutical industry, particularly in drug development across a range of therapeutic areas including oncology. His expertise is expected to play a crucial role in advancing TransCode’s programs aimed at treating metastatic and recurrent cancers.

Philippe P. Calais, the Chief Executive Officer of TransCode, expressed optimism regarding Dr. Janicot’s addition, stating, "Michel's extensive leadership in drug development will strengthen and guide our efforts as TransCode advances its growing oncology pipeline." The company is particularly focusing on two of its lead therapeutic programs—TTX-MC138 and Seviprotimut-L, both of which are designed to offer new avenues in cancer treatment.

Dr. Janicot's journey in the industry began after earning a Ph.D. in Biochemistry from Université Paris VII in France. He gained early experience at Rhône-Poulenc Rorer, further honing his skills at Janssen Pharmaceutica, where he led pivotal preclinical and translational programs. His role at Janssen involved overseeing a diverse portfolio that included drugs for oncology, immunology, inflammation, and fibrosis.

Since 2012, Dr. Janicot has been the Founder and Managing Director of JMi ONConsulting, a consulting firm based in Brussels. His work there focused on providing strategic support for early-stage pharmaceutical development, guiding several leading biotechnology firms in Europe and the United States in their oncology research and development strategies. Notably, he also co-founded the aPODD Foundation, a UK-based nonprofit that works to expedite drug development for pediatric oncology, an area often overlooked by larger corporate initiatives.

On expressing his enthusiasm for joining TransCode, Dr. Janicot said, "I am thrilled to join TransCode at such a pivotal stage in its growth. The company's pioneering pipeline and RNA platform offer a unique opportunity to intercept key drivers of advanced cancers." This statement foreshadows the potential innovations that could emerge from TransCode’s expanding research and development efforts under his guidance.

In his capacity as Senior Development Officer, Dr. Janicot will be tasked with supporting strategic R&D initiatives and playing a vital role in shaping the clinical development strategies for TransCode's investigational oncology programs as they progress toward late-stage clinical trials.

His remarkable background in scientific research includes serving on several international scientific boards, along with authoring and co-authoring over 360 pieces of academic work—from lectures and patents to book chapters and peer-reviewed publications. His extensive knowledge spans all facets of the drug development process, from discovery to preclinical dossier preparation and early clinical development, making him a formidable addition to TransCode’s team.

About TransCode Therapeutics

TransCode Therapeutics specializes in immuno-oncology and targeted therapies designed to tackle advanced malignancies. Their lead candidate, TTX-MC138, specifically targets metastatic tumors with high levels of microRNA-10b, which has been well-documented as a pivotal biomarker for metastasis. The company's portfolio includes groundbreaking treatments aimed at mobilizing the immune system to effectively identify and eliminate cancer cells.

The company advises stakeholders that this release contains forward-looking statements, which are based on current expectations and subject to potential risks that could result in deviations from anticipated outcomes. This advisory underscores the volatile nature of the pharmaceutical industry, where developments can significantly impact both operational strategies and market performance.

For investors and interested parties, keeping an eye on TransCode’s progress with Dr. Janicot at the helm of its development team may provide insight into the future of cancer treatment innovations.